Cargando…
Angiopoietin-like protein 4 and cardiovascular function in COPD
INTRODUCTION: The coexistence of chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD) is frequent and might be inter-related through inflammation-related processes reflected by specific markers. Here, we studied angiopoietin-like protein 4 (ANGPTL4), an upcoming cardiovascul...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133419/ https://www.ncbi.nlm.nih.gov/pubmed/27933182 http://dx.doi.org/10.1136/bmjresp-2016-000161 |
_version_ | 1782471258370211840 |
---|---|
author | Waschki, B Kirsten, AM Holz, O Meyer, T Lichtinghagen, R Rabe, KF Magnussen, H Welte, T Watz, H Janciauskiene, S |
author_facet | Waschki, B Kirsten, AM Holz, O Meyer, T Lichtinghagen, R Rabe, KF Magnussen, H Welte, T Watz, H Janciauskiene, S |
author_sort | Waschki, B |
collection | PubMed |
description | INTRODUCTION: The coexistence of chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD) is frequent and might be inter-related through inflammation-related processes reflected by specific markers. Here, we studied angiopoietin-like protein 4 (ANGPTL4), an upcoming cardiovascular marker, in stable COPD, and its relationship to cardiovascular function with respect to well-known CVD risk factors. METHODS: In a prospective COPD cohort study, we investigated serum ANGPTL4 levels, vascular status (ankle–brachial index (ABI)) and cardiac function (N-terminal pro-B-type natriuretic peptide (NT-proBNP)) as well as airflow limitation, objectively measured physical activity, the metabolic syndrome, high-sensitive C reactive protein (hs-CRP) and other CVD risk factors at 2 time points. We initially studied 74 stable COPD patients and 18 controls. For internal validation, we additionally studied 160 COPD patients of a former visit. RESULTS: ANGPTL4 was significantly elevated in COPD patients compared with controls (p=0.026). After correction for traditional CVD risk factors, including hs-CRP, higher levels of ANGPTL4 were independently associated with lower ABI (p=0.023) and higher NT-proBNP (p<0.001). These findings were confirmed in the internal validation analysis, which included echocardiographic assessments. CONCLUSIONS: Serum ANGPTL4 is independently associated with cardiovascular function in COPD and might qualify as a biomarker reflecting a pathogenic link between COPD and CVD. |
format | Online Article Text |
id | pubmed-5133419 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-51334192016-12-08 Angiopoietin-like protein 4 and cardiovascular function in COPD Waschki, B Kirsten, AM Holz, O Meyer, T Lichtinghagen, R Rabe, KF Magnussen, H Welte, T Watz, H Janciauskiene, S BMJ Open Respir Res Chronic Obstructive Pulmonary Disease INTRODUCTION: The coexistence of chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD) is frequent and might be inter-related through inflammation-related processes reflected by specific markers. Here, we studied angiopoietin-like protein 4 (ANGPTL4), an upcoming cardiovascular marker, in stable COPD, and its relationship to cardiovascular function with respect to well-known CVD risk factors. METHODS: In a prospective COPD cohort study, we investigated serum ANGPTL4 levels, vascular status (ankle–brachial index (ABI)) and cardiac function (N-terminal pro-B-type natriuretic peptide (NT-proBNP)) as well as airflow limitation, objectively measured physical activity, the metabolic syndrome, high-sensitive C reactive protein (hs-CRP) and other CVD risk factors at 2 time points. We initially studied 74 stable COPD patients and 18 controls. For internal validation, we additionally studied 160 COPD patients of a former visit. RESULTS: ANGPTL4 was significantly elevated in COPD patients compared with controls (p=0.026). After correction for traditional CVD risk factors, including hs-CRP, higher levels of ANGPTL4 were independently associated with lower ABI (p=0.023) and higher NT-proBNP (p<0.001). These findings were confirmed in the internal validation analysis, which included echocardiographic assessments. CONCLUSIONS: Serum ANGPTL4 is independently associated with cardiovascular function in COPD and might qualify as a biomarker reflecting a pathogenic link between COPD and CVD. BMJ Publishing Group 2016-10-31 /pmc/articles/PMC5133419/ /pubmed/27933182 http://dx.doi.org/10.1136/bmjresp-2016-000161 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Chronic Obstructive Pulmonary Disease Waschki, B Kirsten, AM Holz, O Meyer, T Lichtinghagen, R Rabe, KF Magnussen, H Welte, T Watz, H Janciauskiene, S Angiopoietin-like protein 4 and cardiovascular function in COPD |
title | Angiopoietin-like protein 4 and cardiovascular function in COPD |
title_full | Angiopoietin-like protein 4 and cardiovascular function in COPD |
title_fullStr | Angiopoietin-like protein 4 and cardiovascular function in COPD |
title_full_unstemmed | Angiopoietin-like protein 4 and cardiovascular function in COPD |
title_short | Angiopoietin-like protein 4 and cardiovascular function in COPD |
title_sort | angiopoietin-like protein 4 and cardiovascular function in copd |
topic | Chronic Obstructive Pulmonary Disease |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133419/ https://www.ncbi.nlm.nih.gov/pubmed/27933182 http://dx.doi.org/10.1136/bmjresp-2016-000161 |
work_keys_str_mv | AT waschkib angiopoietinlikeprotein4andcardiovascularfunctionincopd AT kirstenam angiopoietinlikeprotein4andcardiovascularfunctionincopd AT holzo angiopoietinlikeprotein4andcardiovascularfunctionincopd AT meyert angiopoietinlikeprotein4andcardiovascularfunctionincopd AT lichtinghagenr angiopoietinlikeprotein4andcardiovascularfunctionincopd AT rabekf angiopoietinlikeprotein4andcardiovascularfunctionincopd AT magnussenh angiopoietinlikeprotein4andcardiovascularfunctionincopd AT weltet angiopoietinlikeprotein4andcardiovascularfunctionincopd AT watzh angiopoietinlikeprotein4andcardiovascularfunctionincopd AT janciauskienes angiopoietinlikeprotein4andcardiovascularfunctionincopd |